http://www.PR.com/ Latest news releases from PR.com for Samaritan Pharmaceuticals. Tue, 14 Feb 2012 15:08:37 -0500 © 2012 PR Worldwide, Inc. 60 en-us http://www.PR.com/images/logo_white.jpg http://www.PR.com/ 68 69 PR.com provides Free Press Release Distribution, & is a unique Directory of Businesses, Products, Services, & Jobs - in all industries. Find Full Company Profiles. http://www.pr.com/press-release/66892 Wed, 09 Jan 2008 03:00:00 -0500 Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. [PR.com] http://www.pr.com/press-release/66892 Samaritan Pharmaceuticals http://www.pr.com/press-release/66898 Wed, 09 Jan 2008 03:00:00 -0500 Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. [PR.com] http://www.pr.com/press-release/66898 Samaritan Pharmaceuticals http://www.pr.com/press-release/66908 Wed, 09 Jan 2008 03:00:00 -0500 Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. [PR.com] http://www.pr.com/press-release/66908 Samaritan Pharmaceuticals http://www.pr.com/press-release/66912 Wed, 09 Jan 2008 03:00:00 -0500 Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan Pharmaceuticals Inc. is pleased to announced today that it has signed a service agreement with Advinus Therapeutics Limited, India, to [PR.com] http://www.pr.com/press-release/66912 Samaritan Pharmaceuticals http://www.pr.com/press-release/66302 Fri, 04 Jan 2008 03:00:00 -0500 The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. [PR.com] http://www.pr.com/press-release/66302 Samaritan Pharmaceuticals http://www.pr.com/press-release/66293 Thu, 03 Jan 2008 09:40:52 -0500 Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health is the competent authority to grant approvals to market pharmaceutical drugs in Cyprus, similar to the FDA in the United [PR.com] http://www.pr.com/press-release/66293 Samaritan Pharmaceuticals http://www.pr.com/press-release/66294 Thu, 03 Jan 2008 09:40:46 -0500 Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. [PR.com] http://www.pr.com/press-release/66294 Samaritan Pharmaceuticals http://www.pr.com/press-release/66295 Thu, 03 Jan 2008 09:40:43 -0500 Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. [PR.com] http://www.pr.com/press-release/66295 Samaritan Pharmaceuticals http://www.pr.com/press-release/66300 Thu, 03 Jan 2008 09:40:33 -0500 Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. [PR.com] http://www.pr.com/press-release/66300 Samaritan Pharmaceuticals http://www.pr.com/press-release/66289 Tue, 27 Nov 2007 05:25:00 -0500 In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of [PR.com] http://www.pr.com/press-release/66289 Samaritan Pharmaceuticals http://www.pr.com/press-release/66299 Wed, 03 Oct 2007 17:25:00 -0400 Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. [PR.com] http://www.pr.com/press-release/66299 Samaritan Pharmaceuticals http://www.pr.com/press-release/66303 Tue, 21 Aug 2007 17:25:00 -0400 Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. [PR.com] http://www.pr.com/press-release/66303 Samaritan Pharmaceuticals http://www.pr.com/press-release/66304 Thu, 16 Aug 2007 17:25:00 -0400 Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. [PR.com] http://www.pr.com/press-release/66304 Samaritan Pharmaceuticals